raapivat

Raapivat is an investigational oral small-molecule activator of the enzyme pyruvate kinase in red blood cells (PKR). By allosterically enhancing PKR activity, raapivat increases ATP production and improves energy metabolism in erythrocytes, with the goal of reducing hemolysis and improving anemia in hereditary pyruvate kinase deficiency (PKD), a rare inherited disorder caused by mutations in the PKLR gene.

Mechanism of action: PKR catalyzes a key glycolytic step in red blood cells. Activating PKR shifts energy balance toward higher ATP, helping to stabilize red cell membranes and reduce the hemolysis that characterizes PKD.

Clinical development: Raapivat has been studied in phase 1 and phase 2 clinical trials in adults and, in some programs, pediatric patients with PKD. Trials have evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy. Early results have shown pharmacodynamic engagement of PKR and possible improvements in hemoglobin and markers of hemolysis in some participants, but larger, randomized studies are ongoing to determine robust clinical benefit and optimal dosing.

Regulatory status: Raapivat is not approved for any indication and is being studied in clinical trials. Its development status may change as new data emerge.

See also: Pyruvate kinase deficiency, Mitapivat (another PKR activator), Etavopivat (PKR activator).